[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN109651290B - Preparation method of mirabegron - Google Patents

Preparation method of mirabegron Download PDF

Info

Publication number
CN109651290B
CN109651290B CN201811283756.6A CN201811283756A CN109651290B CN 109651290 B CN109651290 B CN 109651290B CN 201811283756 A CN201811283756 A CN 201811283756A CN 109651290 B CN109651290 B CN 109651290B
Authority
CN
China
Prior art keywords
mirabegron
amino
reaction
reduction
condensation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201811283756.6A
Other languages
Chinese (zh)
Other versions
CN109651290A (en
Inventor
黄欢
黄庆国
李凯
施亚琴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anhui Qingyun Medicine Co ltd
Original Assignee
Anhui Qingyun Medicine Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anhui Qingyun Medicine Co ltd filed Critical Anhui Qingyun Medicine Co ltd
Priority to CN201811283756.6A priority Critical patent/CN109651290B/en
Publication of CN109651290A publication Critical patent/CN109651290A/en
Application granted granted Critical
Publication of CN109651290B publication Critical patent/CN109651290B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/40Unsubstituted amino or imino radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention discloses a preparation method of mirabegron, which comprises the following steps: s1, carrying out reduction reaction on p-nitroacetonitrile to obtain p-nitroacetophenol; s2, performing condensation reduction on p-nitrophenylacetaldehyde and (R) -2-amino-1-phenylethyl alcohol to obtain (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethyl alcohol; s3, carrying out reduction reaction on (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethanol to obtain an intermediate (R) -2- ((4-aminophenylethyl) amino) -1-phenylethanol; s4, condensing (R) -2- ((4-aminophenethyl) amino) -1-phenyl ethanol and aminothiazole acetic acid to obtain the mirabegron. The preparation method of mirabegron provided by the invention has the advantages of cheap and easily-obtained starting materials, controllable reaction conditions, few steps of synthetic route, high yield, low cost and high purity of the prepared mirabegron.

Description

Preparation method of mirabegron
Technical Field
The invention relates to the technical field of pharmaceutical preparations, in particular to a preparation method of mirabegron.
Background
Mirabegron is developed by astela pharmaceutical company (astella) of japan, and the pharmaceutical company, japan, 1997, 10, 17, applied for the compound patent of mirabegron, protected the preparation method thereof, and currently applied for patent protection in several countries and regions, such as the united states, europe, and china, 2011, 9, 16, mirabegron is marketed in japan, 2012, 6, and approved by the U.S. FDA in the united states. The successful marketing of mirabegron, the first orally effective beta 3 adrenoceptor agonist drug for the treatment of overactive bladder, fills the gap in the treatment of overactive bladder with beta adrenoceptor agonists.
The currently disclosed synthetic routes mainly include the following:
the first synthetic route is as follows: patent WO9920607A1 reports a synthesis method using R-styrene oxide as a starting material, in the method, p-nitrophenylethylamine and R-styrene oxide are subjected to ring opening reaction firstly, secondary amine is protected by a protective agent, palladium-carbon catalytic reduction is performed, and finally mirabegron is obtained through condensation and deprotection.
Figure BDA0001848586370000011
This route is the earliest synthetic route for mirabegron. The route requires multiple steps for column chromatography separation, and has the advantages of long steps, low yield, high cost and difficulty in realizing industrial production.
The second synthetic route is as follows: patent WO2015044965A1 reports a synthesis method of mirabegron, which takes R-mandelic acid as a starting material, and obtains the mirabegron by condensation with p-nitroaniline hydrochloride, reduction of amide carbonyl by a borane-tetrahydrofuran system, catalytic reduction of nitro by palladium-carbon and condensation with aminothiazole acetic acid.
Figure BDA0001848586370000021
The mirabegron is obtained by four-step reaction in the route, which seems to be an industrialized route with a wide prospect, but the reaction uses a condensation reagent with high price, uses borane with high toxicity and high risk, uses the condensation reagent EDCl twice, has high cost, and is difficult to realize industrialized large-scale production.
The third synthetic route is as follows: chinese patent CN103232352A reports a synthetic route using p-aminophenylethanol as a starting material, which is subjected to amino protection, alcohol oxidation, condensation, reduction, deprotection, and finally condensation with aminothiazole acetic acid to obtain mirabegron.
Figure BDA0001848586370000022
The route is a brand new route, but the route uses potassium permanganate with high pollution by oxidation, and the starting raw materials are not easy to obtain, so that the industrial production is difficult to realize.
As can be seen from the above review, the current synthesis of mirabegron has a broad prospect because the synthesis route is too long and the yield is low, or because expensive reagents are used and the cost is high, or because the starting materials which are difficult to obtain are used, so that the industrial production is difficult to realize.
Disclosure of Invention
Based on the technical problems in the background art, the invention provides a preparation method of mirabegron.
The invention provides a preparation method of mirabegron, which comprises the following steps:
s1, carrying out reduction reaction on p-nitroacetonitrile to obtain p-nitroacetophenol;
s2, performing condensation reduction on p-nitrophenylacetaldehyde and (R) -2-amino-1-phenylethyl alcohol to obtain (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethyl alcohol;
s3, carrying out reduction reaction on (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethanol to obtain an intermediate (R) -2- ((4-aminophenylethyl) amino) -1-phenylethanol;
s4, condensing (R) -2- ((4-aminophenethyl) amino) -1-phenyl ethanol and aminothiazole acetic acid to obtain the mirabegron.
Preferably, in S1, diisobutyl aluminum hydride is used as a reducing agent in the reduction reaction, and the molar ratio of diisobutyl aluminum hydride to p-nitrophenylacetonitrile is 1.1-1.5: 1.
Preferably, in S1, the molar ratio of diisobutylaluminum hydride to p-nitrophenylacetonitrile is 1.2: 1.
Preferably, in S2, the condensation reduction temperature is-78 ℃ to 50 ℃.
Preferably, in S2, the condensation reduction temperature is 0-10 ℃.
Preferably, in S2, the condensation reduction temperature is-20 to 20 ℃.
Preferably, in S2, the condensation reduction temperature is 0 ℃.
Preferably, in S2, at least one of diethylamine, triethylamine, pyridine, and 4-N, N-lutidine is used as a catalyst during the condensation reaction.
Preferably, triethylamine is selected as the catalyst in the condensation reaction in S2.
Preferably, in S2, at least one of sodium borohydride, potassium borohydride, and sodium triacetoxyborohydride is used as a reducing agent in the condensation reduction process; preferably, sodium borohydride is used as a reducing agent in the condensation reduction process.
Preferably, in S3, the reaction system in the reduction reaction is an ammonium formate-Pd/C system.
Preferably, in S3, the reduction reaction temperature is 10-65 ℃.
Preferably, in S3, the reduction reaction temperature is 55 ℃.
Preferably, in S3, the reduction reaction time is 2-8 hours; preferably, the reduction reaction time is 6 hours.
Preferably, in S4, 4-dimethylaminopyridine is used as a catalyst in the condensation reaction.
The invention has the beneficial effects that:
the invention is a brand new synthetic route, the synthetic route is short, cheap and easily available p-nitroacetonitrile is used as an initial raw material, over-temperature and cheap diisobutyl aluminum hydride is reduced, the reaction yield is high, the purity is high, an amine alkylate is obtained by adopting a Schiff base mode, boron trifluoride ether with certain corrosivity is avoided, nitro is reduced by catalysis of green ammonium formate on palladium-carbon, and finally the mirabegron is obtained by condensation. The mirabegron prepared by the method has the advantages of high purity, few steps, low cost, mild and controllable conditions, simple and convenient operation, suitability for industrial production, wide market prospect and industrial application value.
Detailed Description
The technical solution of the present invention will be described in detail below with reference to specific examples.
Example 1
The invention provides a preparation method of mirabegron, which comprises the following steps:
s1, carrying out reduction reaction on p-nitroacetonitrile to obtain p-nitroacetophenol;
s2, performing condensation reduction on p-nitrophenylacetaldehyde and (R) -2-amino-1-phenylethyl alcohol to obtain (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethyl alcohol;
s3, carrying out reduction reaction on (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethanol to obtain an intermediate (R) -2- ((4-aminophenylethyl) amino) -1-phenylethanol;
s4, condensing (R) -2- ((4-aminophenethyl) amino) -1-phenyl ethanol and aminothiazole acetic acid to obtain the mirabegron.
Example 2
The invention provides a preparation method of mirabegron, which comprises the following steps:
s1, carrying out reduction reaction on the p-nitroacetonitrile by using diisobutylaluminum hydride as a reduction reagent to obtain p-nitroacetophenone; wherein the molar ratio of diisobutylaluminum hydride to p-nitrophenylacetonitrile is 1.1: 1;
s2, using diethylamine and 4-N, N-dimethylpyridine as catalysts, and carrying out condensation reduction on p-nitroacetophenol and (R) -2-amino-1-phenethyl alcohol through potassium borohydride, wherein the condensation reduction temperature is-78 ℃, so as to obtain (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethanol;
s3, carrying out reduction reaction on (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethanol to obtain an intermediate (R) -2- ((4-aminophenylethyl) amino) -1-phenylethanol; wherein the reaction system in the reduction reaction is an ammonium formate-Pd/C system; the reduction reaction temperature is 10 ℃, and the reduction reaction time is 8 hours;
s4, condensing (R) -2- ((4-aminophenyl ethyl) amino) -1-phenyl ethanol and aminothiazole acetic acid by using 4-dimethylamino pyridine as a catalyst to obtain the mirabegron.
Example 3
The invention provides a preparation method of mirabegron, which comprises the following steps:
s1, carrying out reduction reaction on the p-nitroacetonitrile by using diisobutylaluminum hydride as a reduction reagent to obtain p-nitroacetophenone; wherein the molar ratio of diisobutylaluminum hydride to p-nitrophenylacetonitrile is 1.5: 1;
s2, using pyridine as a catalyst, and carrying out condensation reduction on p-nitroacetophenol and (R) -2-amino-1-phenylethyl alcohol by sodium triacetoxyborohydride, wherein the condensation reduction temperature is 50 ℃ to obtain (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethyl alcohol;
s3, carrying out reduction reaction on (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethanol to obtain an intermediate (R) -2- ((4-aminophenylethyl) amino) -1-phenylethanol; wherein the reaction system in the reduction reaction is an ammonium formate-Pd/C system; the reduction reaction temperature is 65 ℃, and the reduction reaction time is 2 hours;
s4, condensing (R) -2- ((4-aminophenyl ethyl) amino) -1-phenyl ethanol and aminothiazole acetic acid by using 4-dimethylamino pyridine as a catalyst to obtain the mirabegron.
Example 4
The invention provides a preparation method of mirabegron, which comprises the following synthetic route:
Figure BDA0001848586370000061
the method comprises the following steps:
s1, synthesis of p-nitroacetophenone (MB-03):
under the protection of nitrogen, sequentially adding 2000mL of toluene and 300g (1.85mol, 1.0eq) of p-nitroacetonitrile into a 5000mL four-neck flask with a mechanical stirrer, reducing the temperature of a reaction system to 0 ℃, slowly dropwise adding 2220mL (2.22mol, 1.2eq) of diisobutylaluminum hydride (DIBAL-H) toluene solution of 1.0mol/L, controlling the temperature of the reaction system to be 10 ℃, continuously stirring for 2 hours after dropwise adding is finished, pouring the reaction solution into 5 wt% of dilute hydrochloric acid, extracting with toluene, drying and concentrating to obtain 284g of p-nitroacetaldehyde, wherein the yield is 92%, and the purity is 99.3%;
synthesis of S2, (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethanol (MB-04):
under the protection of nitrogen, 2000mL of methanol, 280g (1.7mol, 1.1eq) of p-nitroacetophenol, (1.7mol, 1.1eq) of (R) -2-amino-1-phenethyl alcohol and 205g (2.03mol, 1.2eq) of triethylamine are sequentially added into a 5000mL four-neck flask with a mechanical stirrer, the mixture is stirred for 2 hours at room temperature, the temperature of a reaction system is reduced to 0 ℃, 77g (2.03mol, 1.2eq) of sodium borohydride is slowly added in batches, the mixture is kept at 0 ℃ for reaction for 1 hour after the addition, sampling is carried out for HPLC detection, after the conversion of raw materials is completed, 500mL of water is added into the reaction system for quenching, extraction is carried out by dichloromethane, drying and concentration are carried out to obtain 427g of R-2- ((4-nitrobenzyl) amino) -1-phenylethanol, the purity of which is 98.4%, and the yield of 87%.
Synthesis of S3, (R) -2- ((4-aminophenylethyl) amino) -1-phenylethanol (MB-05):
in a 5000mL four-necked flask, 322g (1.0mol, 1.0eq) of (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethanol (MB-04), 3200mL of methanol, 315g (5.0mol,5.0eq) of ammonium formate, Pd/C16g (0.05meq) were added in one portion; heating to 50 ℃ for reaction for 6h, monitoring by HPLC that the reaction is completely converted, filtering, and concentrating the filtrate to dryness; adding 1500mL of water into the concentrated residue, adjusting pH to 10 with 10 wt% sodium hydroxide to precipitate a large amount of white solid, filtering the product, and drying to obtain 241g of off-white solid with yield of 94% and purity of 98.6%;
s4, synthesis of Mirabegron (MB):
in a 5000mL four-mouth reaction flask, 220g (0.86mol,1.0eq) of intermediate (R) -2- ((4-aminophenethyl) amino) -1-phenylethanol and 136g (0.86mol,1.0eq) of aminothiazole acetic acid were added to a reaction kettle, 100mL of concentrated hydrochloric acid and 52g (0.43mol,0.5eq) of 4-Dimethylaminopyridine (DMAP) were sequentially added under mechanical stirring, the mixture was stirred at room temperature for 6 hours, 10 wt% of sodium hydroxide was adjusted to pH 12, a large amount of solid was precipitated, a white-like solid was obtained by filtration, and 269g of white solid mirabegron was obtained by recrystallization from 800mL of isopropanol, the yield was 79%, and the purity was 99.6%.
Example 5
The invention provides a preparation method of mirabegron, which comprises the following steps:
s1, synthesis of p-nitroacetophenone:
under the protection of nitrogen, sequentially adding 2000mL of toluene and 300g (1.85mol, 1.0eq) of p-nitroacetonitrile into a 5000mL four-neck flask with a mechanical stirrer, reducing the temperature of a reaction system to 0 ℃, slowly dropwise adding 2780mL (2.78mol, 1.5eq) of diisobutylaluminum hydride (DIBAL-H) toluene solution of 1.0mol/L, controlling the temperature of the reaction system to be-10 ℃, continuously stirring for 3 hours after the dropwise addition is finished, pouring the reaction solution into 8 wt% of dilute hydrochloric acid, extracting by toluene, drying and concentrating to obtain p-nitroacetophenol;
s2 synthesis of (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethanol:
under the protection of nitrogen, 2000mL of methanol, 280g (1.7mol, 1.1eq) of p-nitroacetophenol, (1.7mol, 1.1eq) of (R) -2-amino-1-phenylethyl alcohol and 205g (2.03mol, 1.2eq) of triethylamine are sequentially added into a 5000mL four-neck flask with a mechanical stirrer, the mixture is stirred for 2 hours at room temperature, the temperature of a reaction system is reduced to 0 ℃, 77g (2.03mol, 1.2eq) of sodium borohydride is slowly added in batches, after the addition is finished, the mixture is kept at-10 ℃ for reaction for 1.5 hours, a sample is sampled for HPLC detection, after the conversion of raw materials is completed, 500mL of water is added into the reaction system for quenching, and the mixture is extracted by dichloromethane, dried and concentrated to obtain R-2- ((4-nitrophenylethyl) amino) -1-phenylethyl alcohol.
S3 synthesis of (R) -2- ((4-aminophenylethyl) amino) -1-phenylethanol:
in a 5000mL four-necked flask, 322g (1.0mol, 1.0eq) of (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethanol (MB-04), 3200mL of methanol, 315g (5.0mol,5.0eq) of ammonium formate, Pd/C16g (0.05meq) were added in one portion; heating to 60 ℃ for reaction for 4h, monitoring by HPLC that the reaction conversion is complete, filtering, and concentrating the filtrate to dryness; adding 1500mL of water into the concentrated residue, adjusting the pH to 10 with 10 wt% of sodium hydroxide to precipitate a large amount of white solid, and filtering and drying the product to obtain a white-like solid;
s4, synthesis of Mirabegron (MB):
in a 5000mL four-mouth reaction bottle, 220g (0.86mol,1.0eq) of intermediate (R) -2- ((4-aminophenethyl) amino) -1-phenylethanol and 136g (0.86mol,1.0eq) of aminothiazole acetic acid are added into a reaction kettle, 100mL of concentrated hydrochloric acid and 52g (0.43mol,0.5eq) of 4-Dimethylaminopyridine (DMAP) are sequentially added under mechanical stirring, the mixture is stirred at room temperature for 6 hours, the pH value is adjusted to 12 by 10 wt% of sodium hydroxide, a large amount of solid is separated out, a white-like solid is obtained by filtering, and white solid mirabegron is obtained by recrystallization of 900mL isopropanol.
Example 6
The invention provides a preparation method of mirabegron, which comprises the following steps:
s1, synthesis of p-nitroacetophenone:
under the protection of nitrogen, sequentially adding 2000mL of toluene and 300g (1.85mol, 1.0eq) of p-nitroacetonitrile into a 5000mL four-neck flask with mechanical stirring, reducing the temperature of a reaction system to 0 ℃, slowly dropwise adding 2040mL (2.04mol, 1.1eq) of diisobutylaluminum hydride (DIBAL-H) toluene solution of 1.0mol/L, controlling the temperature of the reaction system to be 40 ℃, continuously stirring for 0.5H after the dropwise addition is finished, pouring the reaction solution into 5 wt% of dilute hydrochloric acid, extracting by toluene, drying and concentrating to obtain p-nitroacetophenol;
s2 synthesis of (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethanol:
under the protection of nitrogen, 2000mL of methanol, 280g (1.7mol, 1.1eq) of p-nitroacetophenol, (1.7mol, 1.1eq) of (R) -2-amino-1-phenylethyl alcohol and 205g (2.03mol, 1.2eq) of triethylamine are sequentially added into a 5000mL four-neck flask with a mechanical stirrer, the mixture is stirred for 2 hours at room temperature, the temperature of a reaction system is reduced to 0 ℃, 77g (2.03mol, 1.2eq) of sodium borohydride is slowly added in batches, after the addition is finished, the mixture is kept at 5 ℃ for reaction for 0.5 hour, a sample is sampled for HPLC detection, after the conversion of raw materials is completed, 500mL of water is added into the reaction system for quenching, and the mixture is extracted by dichloromethane, dried and concentrated to obtain R-2- ((4-nitrophenylethyl) amino) -1-phenylethyl alcohol.
S3 synthesis of (R) -2- ((4-aminophenylethyl) amino) -1-phenylethanol:
in a 5000mL four-necked flask, 322g (1.0mol, 1.0eq) of (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethanol (MB-04), 3200mL of methanol, 315g (5.0mol,5.0eq) of ammonium formate, Pd/C16g (0.05meq) were added in one portion; heating to 15 ℃ for reaction for 7.5h, monitoring by HPLC that the reaction is completely converted, filtering, and concentrating the filtrate to dryness; adding 1500mL of water into the concentrated residue, adjusting the pH to 10 with 10 wt% of sodium hydroxide to precipitate a large amount of white solid, and filtering and drying the product to obtain a white-like solid;
s4, synthesis of Mirabegron (MB):
in a 5000mL four-mouth reaction bottle, 220g (0.86mol,1.0eq) of intermediate (R) -2- ((4-aminophenethyl) amino) -1-phenylethanol and 136g (0.86mol,1.0eq) of aminothiazole acetic acid are added into a reaction kettle, 100mL of concentrated hydrochloric acid and 52g (0.43mol,0.5eq) of 4-Dimethylaminopyridine (DMAP) are sequentially added under mechanical stirring, the mixture is stirred at room temperature for 6 hours, the pH value is adjusted to 12 by 10 wt% of sodium hydroxide, a large amount of solid is separated out, a white-like solid is obtained by filtering, and white solid mirabegron is obtained by recrystallization through 1000mL of isopropanol.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention should be equivalent or changed within the scope of the present invention.

Claims (10)

1. The preparation method of mirabegron is characterized by comprising the following steps:
s1, carrying out reduction reaction on p-nitroacetonitrile to obtain p-nitroacetophenol;
s2, performing condensation reduction on p-nitrophenylacetaldehyde and (R) -2-amino-1-phenylethyl alcohol to obtain (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethyl alcohol;
s3, carrying out reduction reaction on (R) -2- ((4-nitrophenylethyl) amino) -1-phenylethanol to obtain an intermediate (R) -2- ((4-aminophenylethyl) amino) -1-phenylethanol;
s4, condensing (R) -2- ((4-aminophenethyl) amino) -1-phenyl ethanol and aminothiazole acetic acid to obtain the mirabegron.
2. The method for preparing mirabegron as claimed in claim 1, wherein diisobutylaluminum hydride is used as a reducing agent in the reduction reaction in S1, and the molar ratio of diisobutylaluminum hydride to p-nitroacetonitrile is 1.2: 1.
3. The method for producing mirabegron as claimed in claim 1 or 2, wherein the condensation reduction temperature in S2 is 0 to 10 ℃.
4. The method according to claim 1, wherein the condensation-reduction temperature in S2 is 0 ℃.
5. The method for preparing mirabegron as claimed in claim 1, wherein at least one of diethylamine, triethylamine, pyridine and 4-N, N-dimethylpyridine is used as a catalyst in the condensation reaction in S2.
6. The method for preparing mirabegron as claimed in claim 1, wherein sodium borohydride is used as a reducing agent in the condensation reduction process in S2.
7. The method according to claim 1, wherein the reaction system in the reduction reaction is ammonium formate-Pd/C system in S3.
8. The method according to claim 1, wherein the reduction reaction temperature in S3 is 55 ℃.
9. The method according to claim 1, wherein the reduction reaction time in S3 is 6 hours.
10. The method for preparing mirabegron as claimed in claim 1, wherein 4-dimethylaminopyridine is used as a catalyst in the condensation reaction in S4.
CN201811283756.6A 2018-10-31 2018-10-31 Preparation method of mirabegron Active CN109651290B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811283756.6A CN109651290B (en) 2018-10-31 2018-10-31 Preparation method of mirabegron

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811283756.6A CN109651290B (en) 2018-10-31 2018-10-31 Preparation method of mirabegron

Publications (2)

Publication Number Publication Date
CN109651290A CN109651290A (en) 2019-04-19
CN109651290B true CN109651290B (en) 2022-04-01

Family

ID=66110503

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811283756.6A Active CN109651290B (en) 2018-10-31 2018-10-31 Preparation method of mirabegron

Country Status (1)

Country Link
CN (1) CN109651290B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102350458B1 (en) * 2019-12-11 2022-01-12 주식회사 다산제약 A new process for the preparation of (R)-2-((4-Aminophenethyl)amino)-1-phenylethanol
CN111440126B (en) * 2020-04-03 2023-11-28 湖南复瑞生物医药技术有限责任公司 Preparation method of mirabegron
CN113816864B (en) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 Preparation method of (R) -2-hydroxy-N- [2- (4-aminophenyl) ethyl ] -2-phenethylamine

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103193658A (en) * 2013-04-18 2013-07-10 苏州永健生物医药有限公司 Synthesis method of (R)-2-p-nitrobenzene ethylamine-1-phenethyl alcohol and salt thereof
CN103896872A (en) * 2014-04-29 2014-07-02 黑龙江大学 Method for synthesizing mirabegron
WO2014132270A2 (en) * 2013-02-27 2014-09-04 Msn Laboratories Limited Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
WO2015044965A1 (en) * 2013-09-30 2015-04-02 Megafine Pharma (P) Ltd. A process for preparation of mirabegron and alpha crystalline form thereof
WO2015162536A1 (en) * 2014-04-22 2015-10-29 Calyx Chemicals And Pharmaceuticals Ltd. Novel process for preparation of mirabegron and it's intermediate
WO2016024284A2 (en) * 2014-08-07 2016-02-18 Wanbury Ltd. A process for the preparation of mirabegron and its intermediates
CN106083758A (en) * 2016-06-20 2016-11-09 河南师范大学 A kind of high-efficiency synthesis method of Mirabegron

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014132270A2 (en) * 2013-02-27 2014-09-04 Msn Laboratories Limited Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
CN103193658A (en) * 2013-04-18 2013-07-10 苏州永健生物医药有限公司 Synthesis method of (R)-2-p-nitrobenzene ethylamine-1-phenethyl alcohol and salt thereof
WO2015044965A1 (en) * 2013-09-30 2015-04-02 Megafine Pharma (P) Ltd. A process for preparation of mirabegron and alpha crystalline form thereof
WO2015162536A1 (en) * 2014-04-22 2015-10-29 Calyx Chemicals And Pharmaceuticals Ltd. Novel process for preparation of mirabegron and it's intermediate
CN103896872A (en) * 2014-04-29 2014-07-02 黑龙江大学 Method for synthesizing mirabegron
WO2016024284A2 (en) * 2014-08-07 2016-02-18 Wanbury Ltd. A process for the preparation of mirabegron and its intermediates
CN106083758A (en) * 2016-06-20 2016-11-09 河南师范大学 A kind of high-efficiency synthesis method of Mirabegron

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"米拉贝隆合成工艺改进";范文进 等;《精细化工中间体》;20160831;第46卷(第4期);第42-47页 *
"米拉贝隆和去羟基米拉贝隆的合成";郑亚东 等;《山东化工》;20161231;第45卷(第1期);第3-5,9页 *
"米拉贝隆的合成研究";毛龙飞 等;《化学研究与应用》;20160430;第28卷(第4期);第521-524页 *

Also Published As

Publication number Publication date
CN109651290A (en) 2019-04-19

Similar Documents

Publication Publication Date Title
CN109651290B (en) Preparation method of mirabegron
CN109456277B (en) Preparation method of mirabegron
US5608113A (en) Process for preparation of diamines by catalytic amination of aminoalcohols
CN101851194B (en) Preparation method of nicotinamide
CN107698538B (en) Preparation method of intermediate 3- (1-piperidinylmethyl) phenol of roxatidine acetate hydrochloride
CN110981800A (en) Preparation method of lenvatinib
US11149041B2 (en) Process for the preparation of gadolinium complex of (4S)-4-(4-ethoxybenzyl)-3,6,9-tris(carboxylatomethyl)-3,6,9-triazaundecanedioic acid disodium (Gadoxetate disodium)
CN110511159B (en) Synthesis method of benserazide hydrochloride
CN111393329A (en) Preparation method of ritonavir and lopinavir intermediate
US9902693B2 (en) Preparation method for pyrrolidine-2-carboxylic acid derivatives
CN112552184B (en) Synthetic method of cyclopropyl-containing chiral amine hydrochloride
CN114591216A (en) Method for synthesizing omacycline intermediate
CN114853756B (en) Preparation process of compound Tomivosertib
CN108976140B (en) Preparation method and intermediate of 2-amino-6-ethylbenzoic acid
CN114057668B (en) Synthesis method of amino protecting group chiral 2-amino-3- (4-morpholinylphenyl) propionic acid
CN105566429B (en) Preparation method of obeticholic acid type 1
CN115557891A (en) Preparation method of dextromethorphan
US11780824B2 (en) Process for preparing osimertinib or a salt thereof
CN114853619B (en) Preparation method of N-methyltyramine hydrochloride suitable for industrial production
CA2459175C (en) An improved process for the synthesis of (±)2-amino-n-(2,(2,5-dimethoxyphenyl)-2-hydroxyethyl) acetamide monohydrochloride
CN110963967B (en) Preparation method of 2-methyl-4-aminoquinoline
CN109232471B (en) Preparation method of pramipexole dihydrochloride
JP3870431B2 (en) Process for producing 4,6-bis (substituted) phenylazoresorcinol and its intermediate
CN110577520B (en) Preparation method of 6-nitro-4-substituted amino quinazoline derivative
CN114671869A (en) Novel synthesis method of compound Tomivosertib

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: A preparation method of milabellon

Effective date of registration: 20220701

Granted publication date: 20220401

Pledgee: Hefei SME financing Company limited by guarantee

Pledgor: ANHUI QINGYUN MEDICINE CO.,LTD.

Registration number: Y2022980009683

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20230726

Granted publication date: 20220401

Pledgee: Hefei SME financing Company limited by guarantee

Pledgor: ANHUI QINGYUN MEDICINE CO.,LTD.

Registration number: Y2022980009683

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: A preparation method of Mirabellone

Effective date of registration: 20231229

Granted publication date: 20220401

Pledgee: Industrial Bank Limited by Share Ltd. Hefei branch

Pledgor: ANHUI QINGYUN MEDICINE CO.,LTD.

Registration number: Y2023980075775